ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
Sweetenham
J W
JW
Johnson
P W
PW
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008775:Methylprednisolone / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
D003561:Cytarabine; D005047:Etoposide; D002945:Cisplatin; D008775:Methylprednisolone